DAPA-BODY Trial

DAPA-BODY Trial - DAPA-BODY Trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000048568

Enrollment

100

Registered

2022-08-04

Start date

2021-01-13

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic kidney disease

Interventions

SGLT2 inhibitor dapagliflozin 10 mg/day for 12 months Treatment without SGLT2 inhibitor dapagliflozin for 12 months

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: CKD patients with or without diabetes -15 < eGFR < 59 mL/min/1.73 m2 with or without proteinuria -60 < eGFR mL/min/1.73 m2 with proteinuria

Exclusion criteria

Exclusion criteria: 1. History of renal replacement 2. Current dialysis 3. Type 1 diabetic mellitus 4. Active malignancy

Design outcomes

Primary

Measure	Time frame
body composition (body fluid volume, fat mass, bone mineral content, and skeletal muscle mass) for 6 and 12 months after the administration of dapagliflozin	—

Secondary

Measure	Time frame
changes in hemodynamic parameters and eGFR for 6 and 12 months after the administration of dapagliflozin	—

Countries

Japan

Contacts

Public ContactTAKAHIRO MASUDA

Jichi Medical University Division of Nephrology, Department of Internal Medicine

takamasu35@gmail.com0285587346

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026